All News #Library
Biotech
BioCity, MSD Partner To Evaluate BC3195 + Keytruda In Solid Tumors
13 Mar 2025 //
PR NEWSWIRE
BioCity`s SC0062 Met Primary Endpoint in DKD Phase 2 Trial
25 Feb 2025 //
PR NEWSWIRE
BioCity’s ETA antagonist reduces proteinuria in ph. 2 DKD trial
25 Feb 2025 //
FIERCE BIOTECH
BioCity Reports BC3195 Interim Results At ESMO 2024
23 Sep 2024 //
PR NEWSWIRE
BioCity Gets IND Clearance For Glypican 3 ADC
09 Apr 2024 //
PR NEWSWIRE
BioCity announces first patient dosed with anti-TIM-3 mAb BC3402 with IMFINZI
20 Dec 2023 //
PR NEWSWIRE
BioCity Signs Collaboration Agreement with AstraZeneca on BC3402
27 Sep 2023 //
PR NEWSWIRE
BioCity announces the first patient dosed with ADC BC3195 in a Phase 1 Trial
19 Jul 2023 //
PR NEWSWIRE

Market Place
Sourcing Support